Glycosylation

Vector Laboratories and Navinci Diagnostics Announce Strategic Collaboration to Develop Novel Spatial Proteomic Tools Enabling Biomarker Discovery

Retrieved on: 
Tuesday, January 30, 2024

Vector Laboratories , the pioneer of innovative proteomic and glycomic research solutions, and Navinci Diagnostics , leader of innovative in situ proximity ligation assay-based solutions, today announced that they have signed an agreement.

Key Points: 
  • Vector Laboratories , the pioneer of innovative proteomic and glycomic research solutions, and Navinci Diagnostics , leader of innovative in situ proximity ligation assay-based solutions, today announced that they have signed an agreement.
  • This collaboration aims to develop cutting-edge biomarker discovery tools, allowing detection of specific protein glycosylation in tissue samples for the first time.
  • View the full release here: https://www.businesswire.com/news/home/20240130640005/en/
    The collaboration between Vector Laboratories and Navinci Diagnostics will empower researchers’ ability to understand the glycosylation state of specific protein targets in the spatial context of tissue.
  • “Vector Laboratories’ established legacy as a pioneer in providing innovative, high-quality tools and reagents makes them a fantastic partner in developing this product.

Immunotherapy for Pancreatic Cancer: Peptidic Targeting of a Tumor-Specific Glycan, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, January 24, 2024

TORONTO, Jan. 24, 2024 /PRNewswire-PRWeb/ -- Explore this webinar on a peptide ligand, called molecular guidance system 5 (MGS5), targeting N-glycolylneuraminic acid (Neu5Gc)-Sialyl LewisA in cancer, enhancing early detection and advancing liposome-based immunotherapy for pancreatic cancer.

Key Points: 
  • Attendees will learn about molecular guidance systems (MGSs) that can be identified for virtually any cell type.
  • The featured speaker will discuss a novel immunotherapy to use in combination with checkpoint inhibitors, and more.
  • TORONTO, Jan. 24, 2024 /PRNewswire-PRWeb/ -- Explore this webinar on a peptide ligand, called molecular guidance system 5 (MGS5), targeting N-glycolylneuraminic acid (Neu5Gc)-Sialyl LewisA in cancer, enhancing early detection and advancing liposome-based immunotherapy for pancreatic cancer.
  • Join Shelby Knoche PhD, SRI International , for the live webinar on Wednesday, January 31, 2024, at 2pm EST (11am PST).

Glycomine Announces First Pediatric Patient Dosed in Phase 2 Clinical Study of GLM101, a Potential Treatment for PMM2-CDG

Retrieved on: 
Monday, December 11, 2023

Glycomine, Inc. , a clinical-stage biotechnology company focused on developing new therapies for orphan diseases, announced the first pediatric patient has been dosed in a multi-center open-label Phase 2 study of GLM101, a mannose-1-phosphate replacement therapy, in patients with phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG).

Key Points: 
  • Glycomine, Inc. , a clinical-stage biotechnology company focused on developing new therapies for orphan diseases, announced the first pediatric patient has been dosed in a multi-center open-label Phase 2 study of GLM101, a mannose-1-phosphate replacement therapy, in patients with phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG).
  • “The initiation of dosing in pediatrics is an important milestone for the company,” said Steven Axon, CEO of Glycomine.
  • “We are happy to be a part of an effort that has the potential to make a positive impact on PMM2-CDG patients and the community.”
    Following a dose range finding study that enrolled 10 adult PMM2-CDG patients, this Phase 2 study in pediatric patients with a confirmed diagnosis of PMM2-CDG will be an open-label, 24-week treatment with GLM101 (ClinicalTrials.gov Identifier: NCT05549219 ).
  • The purpose of the study is to evaluate potential pharmacodynamic activity and clinical efficacy, as well as safety, tolerability, and pharmacokinetics of GLM101.

Insect Cell Culture Market Size to Grow USD 3.74 Billion by 2029 at a CAGR of 8.3% | Valuates Reports

Retrieved on: 
Thursday, November 30, 2023

The global Insect Cell Culture market was valued at USD 2.31 Billion in 2022 and is anticipated to reach USD 3.74 Billion by 2029, witnessing a CAGR of 8.3% during the forecast period 2023-2029.

Key Points: 
  • The global Insect Cell Culture market was valued at USD 2.31 Billion in 2022 and is anticipated to reach USD 3.74 Billion by 2029, witnessing a CAGR of 8.3% during the forecast period 2023-2029.
  • Claim Your Free Sample Now: https://reports.valuates.com/request/sample/QYRE-Auto-35F1907/Global_Ins...
    Major Factors Driving the Growth of Insect Cell Culture Market:
    The market for insect cell culture is expanding significantly due to its many uses in biotechnology.
  • The market for insect cell culture is developing due to its growing use in the manufacturing of vaccines.
  • The market for insect cell culture is expanding as a result of increased expenditures made in the biotechnology industry worldwide.

Insect Cell Culture Market Size to Grow USD 3.74 Billion by 2029 at a CAGR of 8.3% | Valuates Reports

Retrieved on: 
Thursday, November 30, 2023

The global Insect Cell Culture market was valued at USD 2.31 Billion in 2022 and is anticipated to reach USD 3.74 Billion by 2029, witnessing a CAGR of 8.3% during the forecast period 2023-2029.

Key Points: 
  • The global Insect Cell Culture market was valued at USD 2.31 Billion in 2022 and is anticipated to reach USD 3.74 Billion by 2029, witnessing a CAGR of 8.3% during the forecast period 2023-2029.
  • Claim Your Free Sample Now: https://reports.valuates.com/request/sample/QYRE-Auto-35F1907/Global_Ins...
    Major Factors Driving the Growth of Insect Cell Culture Market:
    The market for insect cell culture is expanding significantly due to its many uses in biotechnology.
  • The market for insect cell culture is developing due to its growing use in the manufacturing of vaccines.
  • The market for insect cell culture is expanding as a result of increased expenditures made in the biotechnology industry worldwide.

Avalo Completes Divestiture of AVTX-800 Series

Retrieved on: 
Tuesday, October 31, 2023

WAYNE, Pa. and ROCKVILLE, Md., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced it has completed the divestiture of its rights, title and interest in, assets relating to AVTX-801 (D-galactose), AVTX-802 (D-mannose) and AVTX-803 (L-fucose) (collectively, the 800 Series) to AUG Therapeutics, LLC (AUG).

Key Points: 
  • WAYNE, Pa. and ROCKVILLE, Md., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced it has completed the divestiture of its rights, title and interest in, assets relating to AVTX-801 (D-galactose), AVTX-802 (D-mannose) and AVTX-803 (L-fucose) (collectively, the 800 Series) to AUG Therapeutics, LLC (AUG).
  • The Company previously announced it entered into a purchase agreement with AUG to divest the 800 Series on September 12, 2023 (the Purchase Agreement).
  • Additionally, AUG assumed $150,000 of certain liabilities incurred prior to the date of the Purchase Agreement and assumed all costs relating to the 800 Series from the date of the Purchase Agreement.
  • “We are excited to announce that we have closed the transaction with AUG to divest our 800 Series programs for the treatment of congenital disorders of glycosylation (CDGs).

Glycomine Presents at ASHG 2023 Data from Ongoing Natural History Study with Insight into Genetic Mutations and Biomarkers for PMM2-CDG

Retrieved on: 
Thursday, November 2, 2023

Glycomine, Inc. , a biotechnology company focused on developing new therapies for orphan diseases, announced the presentation of summary findings from its ongoing natural history study at the American Society for Human Genetics (ASHG) 2023 Annual Meeting taking place in Washington, DC.

Key Points: 
  • Glycomine, Inc. , a biotechnology company focused on developing new therapies for orphan diseases, announced the presentation of summary findings from its ongoing natural history study at the American Society for Human Genetics (ASHG) 2023 Annual Meeting taking place in Washington, DC.
  • The findings included genotype characterization, combined with the progression of key biomarkers, over two to four years.
  • The effort has resulted in the largest single dataset in patients with PMM2-CDG from a prospective natural history study to date.
  • PB1696) is “Ongoing Natural History Study in Phosphomannomutase 2 Congenital Disorder of Glycosylation (PMM2-CDG): Clinical and Basic Investigations.”

Osmolality Analysis in Bioprocessing: From Theory to Practice, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, November 6, 2023

TORONTO, Nov. 6, 2023 /PRNewswire-PRWeb/ -- Discover an informative webinar exploring the impact of osmolality in bioprocessing and in correlation with immunoglobulin G (IgG) production. Osmolality is described as the measurement of the contribution of all the dissolved solutes to the osmotic pressure of a solution. In biopharma, osmolality is usually used as a critical quality control (QC) check for cell culture media, buffers and formulated drug products. It is also used as a critical process parameter during upstream cell culture and downstream filtration.

Key Points: 
  • Attendees will learn about using osmolality analysis in Chinese hamster ovary (CHO) cell health studies.
  • The featured speakers will discuss current uses and future potential for osmolality analysis at the upstream and downstream stages of bioprocessing.
  • TORONTO, Nov. 6, 2023 /PRNewswire-PRWeb/ -- Discover an informative webinar exploring the impact of osmolality in bioprocessing and in correlation with immunoglobulin G (IgG) production.
  • Join this webinar to gain insights into osmolality in correlation with IgG production in a media development project.

Glycotope and Max Delbrück Center enter into research collaboration to explore combination of GlycoTargets and CAR technology

Retrieved on: 
Monday, September 25, 2023

Berlin, Germany, 25 September 2023 – Glycotope GmbH (Glycotope) and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association have signed an agreement to explore the potential of combining Glycotope’s antibodies against protein/carbohydrate combined glyco-epitopes (GlycoTargets) with chimeric antigen receptor (CAR) technology developed by the Max Delbrück Center.

Key Points: 
  • Berlin, Germany, 25 September 2023 – Glycotope GmbH (Glycotope) and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association have signed an agreement to explore the potential of combining Glycotope’s antibodies against protein/carbohydrate combined glyco-epitopes (GlycoTargets) with chimeric antigen receptor (CAR) technology developed by the Max Delbrück Center.
  • However, in some indications, including harder to treat cancers with solid tumors, success has been limited.
  • In the scope of the newly established collaboration, highly tumor-specific antibodies developed by Glycotope will be combined with the CAR technology of the Max Delbrück Center to analyze their suitability for the treatment of solid tumors.
  • The CAR program at the Max Delbrück Center includes several proprietary antibody binders targeting hematologic tumors.

Avalo Enters into Agreement to Divest AVTX-800 Series

Retrieved on: 
Tuesday, September 12, 2023

, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced it entered into a purchase agreement (the Purchase Agreement) with AUG Therapeutics, LLC (AUG) to sell its rights, title and interest in, assets relating to AVTX-801 (D-galactose), AVTX-802 (D-mannose) and AVTX-803 (L-fucose) (collectively, the 800 Series).

Key Points: 
  • , Sept. 12, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced it entered into a purchase agreement (the Purchase Agreement) with AUG Therapeutics, LLC (AUG) to sell its rights, title and interest in, assets relating to AVTX-801 (D-galactose), AVTX-802 (D-mannose) and AVTX-803 (L-fucose) (collectively, the 800 Series).
  • Additionally, AUG will assume up to $150,000 of certain liabilities incurred prior to the date of the Purchase Agreement and assume all costs relating to the 800 Series from the date of the Purchase Agreement.
  • The transaction is expected to close in the fourth quarter of 2023, subject to customary closing conditions, including obtaining certain third-party consents.
  • “We are excited to announce the transfer of our 800 series programs for the treatment of congenital disorders of glycosylation (CDGs) to AUG.